Akebia Therapeutics (AKBA) vs BioAge Labs (BIOA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
BioAge Labs (BIOA) has outperformed Akebia Therapeutics (AKBA) over the past year, gaining 11.8% versus a loss of 70.4%. BioAge Labs is the larger company by market cap ($287.3 million vs $242.0 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AKBA | BIOA |
|---|---|---|
| Share price | $0.8734 | $6.26 |
| Market cap | $242.02M | $287.31M |
| 1-day change | -0.58% | -0.48% |
| YTD return | -45.75% | -52.68% |
| 1-year return | -70.39% | +11.79% |
| 5-year return | -69.35% | — |
| EPS (TTM) | $-0.12 | $-2.39 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.20 | $25.96 |
| 52-week low | $0.814 | $5.04 |
| Distance from 52-week high | -72.71% | -75.88% |
| Analyst consensus | none | none |
| Avg. price target upside | +348.82% | +469.17% |
| Average volume | 6.09M | 915.59K |
| Shares outstanding | 277.11M | 45.90M |
| Employees | 194 | 60 |
| Sector | Healthcare | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic | Drug Manufacturers - Specialty & Generic |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- BIOA has outperformed AKBA by 82.2 percentage points over the past year.
About Akebia Therapeutics
AKBA stock →Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. Its product portfolio includes Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent (DD) and non-dialysis dependent (NDD) patients; and Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD and the treatment of iron deficiency anemia in adult patients with NDD-CKD.
Healthcare · Drug Manufacturers - Specialty & Generic · 194 employees
About BioAge Labs
BIOA stock →BioAge Labs, Inc., a clinical-stage biopharmaceutical company, develops therapeutic product candidates for metabolic diseases. The company's technology platform and differentiated human datasets that allows users to identify targets based on insights into molecular changes that drive aging.
Healthcare · Drug Manufacturers - Specialty & Generic · 60 employees
AKBA vs BIOA FAQ
Which is bigger, Akebia Therapeutics or BioAge Labs?
BioAge Labs (BIOA) is larger, with a market capitalization of $287.31M compared with $242.02M for Akebia Therapeutics (AKBA).
Which stock has performed better over the past year, AKBA or BIOA?
BIOA returned +11.79% over the past 12 months, compared with -70.39% for AKBA (price return, excluding dividends). Past performance does not predict future results.
Are Akebia Therapeutics and BioAge Labs in the same industry?
Yes. Both are classified in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector.